FDA approves Ascendis Pharma’s once-weekly YUVIWEL for children with achondroplasia aged 2 and older

Reuters06:57
FDA approves Ascendis Pharma’s once-weekly YUVIWEL for children with achondroplasia aged 2 and older

Ascendis Pharma A/S said the U.S. Food and Drug Administration granted accelerated approval for YUVIWEL (navepegritide), a once-weekly treatment indicated to increase linear growth in children aged 2 years and older with achondroplasia with open epiphyses. The company said continued approval may be contingent on confirmatory trials, and that the FDA also issued a Rare Pediatric Disease Priority Review Voucher in connection with the approval. Ascendis expects commercial availability in the United States in the early part of the second quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602271757PRIMZONEFULLFEED9663256) on February 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment